Parkwalk Advisors

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

Cambridge GaN Devices specializes in the design, development, and commercialization of gallium nitride (GaN) power devices aimed at enhancing energy efficiency across various electronic applications. The company produces a range of GaN-based semiconductor products that significantly improve power conversion and minimize energy loss in systems used in sectors such as renewable energy, electric vehicles, and consumer electronics. These transistors are characterized by their speed, reduced power loss, smaller size compared to traditional silicon alternatives, and greater energy storage and conversion capabilities. By collaborating with industry partners, Cambridge GaN Devices promotes innovation and facilitates the adoption of its advanced technology within the power semiconductor market, contributing to the advancement of greener technologies.

Illumion is a technology company specializing in energy storage solutions. It develops and manufactures a lab-based, real-time measurement device that provides detailed insights into energy storage processes at sub-micrometer scales. This device enables researchers to visualize and understand energy storage processes in real-time, optimize material usage, and identify performance limitations at the microscopic level, thereby accelerating battery development and enhancing energy storage efficiency and performance.

PervasID Limited is a company based in Cambridge, United Kingdom, that specializes in the development of wide area passive RFID systems. Founded in 2011, PervasID focuses on providing location capabilities based on the EPC Class1 Gen2 standard. The company emerged from research conducted in the Engineering Department at the University of Cambridge and has since successfully deployed its technology in various field trials. PervasID's innovative RFID tracking system is designed to serve multiple industries, including retail, healthcare, supply chain and logistics, and aviation. Utilizing patented technology, the system employs fixed ultra-high frequency RFID to detect passive tags over long ranges with high accuracy, enabling organizations to enhance visibility into goods, assets, and personnel, thereby streamlining operational processes.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Ikarovec is a gene therapy company focused on developing early-stage treatments for common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, working on therapies that also target dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By advancing these innovative treatments, Ikarovec seeks to provide effective solutions for patients, helping to restore sight and prevent blindness.

Evoralis is an enzyme development company focused on the discovery and enhancement of plastic-depolymerizing enzymes. Originating as a spin-out from the University of Cambridge, the company aims to improve the sustainability of plastics and promote the circular economy of plastic waste. Evoralis has developed a unique screening platform that accelerates the discovery and optimization of biocatalysts, enabling more efficient breakdown of plastics into their fundamental building blocks. This technology facilitates the recycling process, allowing these building blocks to be reused in the creation of new products, thereby addressing the challenges associated with plastic waste and contributing to environmental sustainability.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.

OW Smell Made Digital specializes in innovative solutions for controlling and enhancing olfactory experiences through digital technology. The company develops advanced software and hardware that leverage a powerful algorithm and extensive database to identify various smells and their perceptual effects. This technology enables customers to integrate scent seamlessly into their content, services, or products, providing a unique sensory experience. By combining reliable technical components with digital capabilities, OW Smell Made Digital empowers users to have complete control over scent, allowing for enhanced engagement and interaction across various applications.

Xwatts is a developer of an intelligent energy management system specifically designed for commercial buildings. The company focuses on reducing costs and emissions through continuous analysis of energy usage patterns, environmental conditions, and market data. By optimizing and automating electricity consumption, Xwatts enables building owners to take direct control of their distributed energy assets. The system evaluates historical usage alongside real-time market data to enhance asset scheduling and minimize electricity consumption costs, thereby promoting more efficient energy management in commercial properties.

Psyomics specializes in the development of proteomic diagnostics aimed at improving early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers web-based assessment triage designed to facilitate diagnostic and pathway prediction for mental health conditions. By integrating digital profiling with cutting-edge biological research, Psyomics enhances diagnostic accuracy and supports primary care practitioners in effectively managing their patients' mental health needs. This innovative approach digitally replicates a psychiatric assessment at the initial point of contact, thereby enabling patients to achieve better recovery outcomes from mental health disorders.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Adsilico is a medical technology company that specializes in developing advanced computer simulations to assess the safety and performance of medical devices. By using virtual patients, the company helps clients identify potential issues early in the development process, expedite time to market, and reduce the costs associated with traditional clinical trials.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

MeVitae is an online recruitment platform designed to enhance diversity and inclusivity in the hiring process for organizations. The company provides data-driven technology that enables businesses to better understand their current workforce and attract, screen, and retain top talent. By focusing on personalized hiring aligned with a company's culture, MeVitae ensures a fair and transparent talent acquisition process, free from algorithmic and neurological bias. The platform seamlessly integrates with existing applicant tracking systems (ATS) and customer relationship management (CRM) tools, allowing clients to maintain their established processes while improving their workforce diversity and productivity.

Koalaa specializes in the development of soft prosthetic arms and personalized support solutions for individuals of all ages, including babies, children, and adults. The company aims to enhance the quality of life for its users by providing comfortable and affordable prosthetic options. Its innovative slip-on-and-go prosthetic arm features a soft fabric construction and interchangeable tools, making it lightweight and user-friendly. This design allows wearers to perform everyday tasks with ease while ensuring comfort throughout the day. Koalaa is committed to making its prosthetic products accessible to anyone in need, reinforcing its mission to improve lifestyles through functional and adaptable solutions.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Albus Health is a startup originating from the University of Oxford, focusing on the development of an intelligent nocturnal monitoring platform for personalized home health monitoring. The platform enables passive, contactless, and objective tracking of various symptoms and environmental metrics. This innovative system is designed primarily for use in clinical trials by leading pharmaceutical companies, facilitating the monitoring of nocturnal symptoms and aiding in the prediction of respiratory emergencies. By providing detailed insights into patient conditions, Albus Health's technology supports pharmaceutical firms in optimizing their clinical studies while enhancing revenue potential.

Proxisense is a manufacturer and developer specializing in extreme environment proximity sensors and fluid contamination systems. Utilizing advanced eddy current sensors, the company focuses on providing real-time monitoring solutions for critical applications, particularly in the power and aerospace industries. Proxisense's technology is designed to monitor the health of turbine blades, which helps extend component lifetimes and reduce maintenance and downtime costs. The company addresses significant challenges in fluid contamination, offering reliable monitoring systems that protect transportation assets requiring fuel and lubrication from various sources. By collaborating closely with leading original equipment manufacturers, Proxisense aims to enhance the performance and efficiency of complex rotating equipment, ultimately contributing to the prediction and prevention of costly equipment failures.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

Fresh Check is a simple sticker that you put inside the packaging of food that changes colour when your food has actually gone off, not when the use-by date says so.

Phasecraft is a UK-based company founded in 2018 that specializes in developing quantum software for quantum information processors, including intermediate scale devices and quantum computers. The company is composed of leading quantum scientists and engineers who aim to accelerate the practical application of quantum computing to address significant global challenges. Phasecraft's software is designed to tackle ambitious problems by enabling clients to investigate novel quantum materials and optimize key industrial processes, such as developing batteries and efficient solar cells.

Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on improving access to blood tests through innovative healthcare monitoring devices. Established in 2014, the company offers products such as Aptus, which facilitates haemoglobin and haematocrit testing for various applications, including health screening and maternal and child health. Additionally, Entia provides Affinity, a device designed for cancer patients to monitor their blood counts at home, thereby reducing the risk of infection and minimizing the need for hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, business development, and innovation, aimed at enhancing the management of health conditions from the comfort of patients' homes.

RoboK Limited is a computer vision startup based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing simultaneous localization and mapping (SLAM) algorithms and innovative 3D sensing technologies for various applications, particularly in the automotive and industrial sectors. RoboK aims to enhance safety and performance in industrial workplaces by maximizing the value of existing CCTV systems. Its platform provides a modular and scalable solution for object detection, classification, tracking, and depth estimation, enabling clients to transform passive visual data into actionable insights. The company collaborates with major critical infrastructure operators to optimize their operations through advanced visual analytics.

Cambridge Touch Technologies, Ltd., established in 2011 and based in Cambridge, UK, specializes in developing advanced 3D touch technology for various applications. The company's core product, UltraTouch, combines a proprietary AI engine with an innovative Piezoelectric Force Film to create a simplified, yet powerful touch and force sensor architecture. This technology offers superior functionality, lower costs, and scalability to diverse device sizes and shapes, including curved and foldable ones, catering to smartphones, tablets, automotive, and industrial sectors.

Signaloid is a technology company that specializes in computing platforms and software solutions aimed at uncertainty-tracking in data inputs. Its offerings include a cloud platform and application programming interface that facilitate advanced computations and data storage. The company's technologies are applicable across various fields such as materials modeling, autonomous systems, computational finance, machine learning, and quantum computing. By leveraging its innovations, Signaloid enables clients to assess the impact of uncertainties on their decision-making processes, helping them to ensure compliance with regulations, optimize costs, and enhance safety outcomes.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.

DefiniGEN Limited is a biotechnology company based in Cambridge, United Kingdom, specializing in the production of human cell products for the life science and drug discovery sectors. Founded in 2012, the company utilizes its proprietary OptiDIFF stem cell production platform to create high-functionality cell types, including human hepatocytes and pancreatic cells, which are essential for predictive toxicology and drug discovery. DefiniGEN's offerings encompass a range of disease models, such as those for diabetes, hepatitis, and hypercholesterolemia, facilitating research and development in these areas. The company also provides custom services, including gene-editing custom cell line development and contract services for diabetes compound profiling. By leveraging advanced technologies and expertise in induced pluripotent stem cell production, DefiniGEN aims to enhance the efficacy and safety of new treatments, ultimately benefiting pharmaceutical clients in their research efforts.

Carbometrics is a specialist chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Founded by the team behind the successful development of a glucose-binding molecule platform, the company leverages over 20 years of research from Professor Anthony Davis’ group at the University of Bristol. Carbometrics aims to create a robust and accurate glucose sensing platform that will lead to an innovative Continuous Glucose Monitoring (CGM) solution, enabling individuals with diabetes to monitor their glucose levels more effectively. Following the sale of their previous venture, Ziylo, to Novo Nordisk, the founders are committed to developing advanced technologies to improve the management of diabetes and enhance patients' quality of life.

Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, focused on developing and producing plant protein-based materials as sustainable alternatives to conventional plastics. Founded in 2018, Xampla specializes in creating biodegradable and biocompatible products, including microcapsules, beads, films, threads, and various other structures made entirely from pea protein. These materials are designed for diverse commercial applications, spanning sectors such as food, cosmetics, household products, animal feed, packaging, and medical uses. By eliminating synthetic ingredients and reducing reliance on polluting plastics, Xampla aims to provide environmentally friendly solutions that align with the growing demand for sustainable materials in the marketplace.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

OSSTEC is a company specializing in advanced technology for the operating room, focusing on metal 3D printed bone healing implants. These orthopedic implants are designed to mimic the natural structure of bone, effectively addressing high failure rates associated with conventional implants. By promoting long-term bone growth, OSSTEC's innovative solutions aim to improve the quality of life for patients suffering from osteoarthritis, enabling them to remain healthy, active, and pain-free.

LettUs Grow Ltd. is a company based in Bristol, United Kingdom, founded in 2015, that specializes in aeroponic irrigation and control technology for indoor farming. The company develops innovative systems that enable plants to grow without soil, using a fine mist for watering and LED lighting for photosynthesis. Their modular, nozzle-free aeroponic hardware is designed to be easy to clean and fully automatable, which reduces the reliance on pesticides and minimizes operational costs. In addition to hardware, LettUs Grow provides software and data services that optimize farming practices, enhancing efficiency and sustainability while lowering the environmental impact of agriculture. The company is committed to transforming farming through technology, aiming to create a more sustainable and efficient agricultural industry.

TextMine is an AI-powered knowledge base designed to streamline the management of business-critical documents, such as invoices, contracts, and compliance reports. By utilizing patented knowledge graph technology, TextMine consolidates data into a single operational layer, enhancing the usability and searchability of contract data at scale. This approach facilitates proactive decision-making and improves data transparency, enabling organizations to create documents more uniformly and efficiently. As a result, TextMine assists companies in saving time and reducing costs while minimizing risk and enhancing compliance.

NoBACZ Healthcare is a company focused on developing an innovative precision bandaging platform for both veterinary and human applications. It specializes in creating rapid set liquid barriers that serve as advanced wound care products. These bandages are designed to be sterile, antimicrobial, and biodegradable, allowing for customization to effectively address various wound types. By providing healthcare professionals with tools to manage wound care efficiently, NoBACZ enables the rapid treatment of deep wounds, particularly in veterinary practices and agricultural settings, while minimizing the risk of infections associated with traditional bandaging methods.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Zomp is a provider of consumer electronics.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacture of high-purity, animal-free growth factors, cytokines, and complex proteins designed to support advancements in stem cell, organoid, and regenerative medicine. Utilizing proprietary protein production processes developed at the University of Cambridge, Qkine combines these methodologies with protein engineering techniques to produce unique products that address critical biological and scalability challenges in fast-evolving life science sectors. The company boasts an active research and development pipeline, continually expanding its product offerings, which include innovative solutions such as tag-free thermostable FGF-2 and the first animal-free TGF beta 1 for chemically defined stem cell media. Qkine is committed to quality and is certified under ISO 9001:2015, ensuring that its bioactive proteins meet the highest standards to support its customers' scientific endeavors.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Cambridge GaN Devices specializes in the design, development, and commercialization of gallium nitride (GaN) power devices aimed at enhancing energy efficiency across various electronic applications. The company produces a range of GaN-based semiconductor products that significantly improve power conversion and minimize energy loss in systems used in sectors such as renewable energy, electric vehicles, and consumer electronics. These transistors are characterized by their speed, reduced power loss, smaller size compared to traditional silicon alternatives, and greater energy storage and conversion capabilities. By collaborating with industry partners, Cambridge GaN Devices promotes innovation and facilitates the adoption of its advanced technology within the power semiconductor market, contributing to the advancement of greener technologies.

Enhanc3D Genomics is a biotechnology firm focused on functional genomics, specifically examining the three-dimensional organization of DNA and its implications in health and disease. The company has developed the GenLink3D platform, which facilitates large-scale analysis of genetic variations and gene function by providing high-resolution profiles of genome folding for all genes and their enhancers simultaneously. This innovative technology enables researchers to understand the impact of genetic mutations on distant genes, thereby elucidating their role in disease progression. By advancing knowledge in this area, Enhanc3D Genomics supports the development of novel drug therapies aimed at addressing significant unmet medical needs.

Opsydia Limited, established in 2017 and based in Begbroke, UK, specializes in manufacturing advanced laser marking technology. This technology enables the creation of permanent, invisible structures such as serial numbers, images, and cryptographic data within transparent materials like diamonds, glass, polymers, and plastics without altering their surface or integrity. Opsydia's innovative solution aims to disrupt various industries by enhancing security, traceability, and authenticity in transparent materials.

PervasID Limited is a company based in Cambridge, United Kingdom, that specializes in the development of wide area passive RFID systems. Founded in 2011, PervasID focuses on providing location capabilities based on the EPC Class1 Gen2 standard. The company emerged from research conducted in the Engineering Department at the University of Cambridge and has since successfully deployed its technology in various field trials. PervasID's innovative RFID tracking system is designed to serve multiple industries, including retail, healthcare, supply chain and logistics, and aviation. Utilizing patented technology, the system employs fixed ultra-high frequency RFID to detect passive tags over long ranges with high accuracy, enabling organizations to enhance visibility into goods, assets, and personnel, thereby streamlining operational processes.

Crypto Quantique is a London-based cybersecurity company founded in 2015. It specializes in developing quantum-driven secure chips (QDSC) integrated into silicon, which generate cryptographic keys using quantum processes in nano-devices. These chips can be incorporated into the development process of connected devices or retrofitted into existing ones. The company focuses on combining advanced quantum technologies with modern cryptography to create next-generation hardware and software products that offer future-proof cybersecurity solutions. Crypto Quantique provides local network-based cyber-security solutions, emphasizing end-to-end IoT security standards.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

Ceryx Medical Limited is a biotechnology company based in Bath, United Kingdom, founded in 2016. The company specializes in developing and manufacturing innovative bio-electronic devices that utilize unique, patent-protected chip technology. These devices are designed to mimic Central Pattern Generators (CPGs), which are nerve centers in the body responsible for regulating various autonomic and rhythmical processes, including peristalsis, heart rate, and walking. Ceryx Medical aims to restore normal physiological functions that may be compromised due to disease or injury by employing artificial CPGs in their therapeutic devices.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

NK:IO is a biotechnology company focused on advancing innovative strategies for natural killer cell-mediated immunotherapy. It specializes in the development of both cell therapies and small molecule therapeutics, with a primary emphasis on cancer treatment. By harnessing the capabilities of natural killer cells, NK:IO aims to enhance the effectiveness of cancer therapies, providing physicians with improved tools to combat the disease. The company's commitment to research and development positions it at the forefront of immunotherapy advancements in the oncology field.

Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, founded in 2017. It operates a user-centric genetic data-sharing platform that empowers individuals to contribute their genetic and health information for research purposes. The platform facilitates a direct connection between users and researchers, enabling the analysis of consented data to advance scientific understanding and personalized medicine. Sano Genetics supports a wide range of studies, including those focused on common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to choose from various research programs, the company aims to enhance recruitment for clinical trials and provide researchers with access to dynamic health and genetic datasets, ultimately contributing to the development of new treatments and cures.

SERG Technologies is focused on transforming the interaction between users and technology through the development of advanced wearables that facilitate activity tracking, health and fitness monitoring, and gesture recognition for smart devices. The company utilizes innovative sensors capable of detecting subtle movements that reflect a user's intent, which are then converted into control signals for a variety of devices, including televisions and smart prosthetics, ensuring rapid response times. Additionally, SERG is committed to enhancing the lives of individuals with Parkinson's disease by creating a digital health platform that provides continuous, personalized assessments of symptoms. This platform delivers actionable insights that empower patients to manage their conditions more effectively, thereby improving their mobility, independence, and overall quality of life. SERG Technologies aims to make gesture control technology accessible and user-friendly for everyone.

BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

OW Smell Made Digital specializes in innovative solutions for controlling and enhancing olfactory experiences through digital technology. The company develops advanced software and hardware that leverage a powerful algorithm and extensive database to identify various smells and their perceptual effects. This technology enables customers to integrate scent seamlessly into their content, services, or products, providing a unique sensory experience. By combining reliable technical components with digital capabilities, OW Smell Made Digital empowers users to have complete control over scent, allowing for enhanced engagement and interaction across various applications.

Semarion is a company that emerged from the Cavendish Laboratory at the University of Cambridge, focusing on innovations at the intersection of physical and life sciences. It specializes in the development of a drug discovery platform utilizing advanced microcarrier technology to enhance the process of adherent cell screening. By integrating materials engineering with cell biology, Semarion offers unique, magnetically steerable microcarriers that support small cell colonies. This innovative approach facilitates more efficient and powerful assay workflows, positioning researchers to expedite the identification of drugs, particularly for GPCR-targeting oncology applications. Semarion aims to address unmet needs in drug screening and accelerate the advancement of new therapeutic options.

Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.

Barocal is a developer of innovative cooling technology focused on meeting low-carbon refrigeration needs. The company utilizes materials that experience significant thermal changes when pressure is applied or removed, leading to enhanced energy efficiency and a zero greenhouse warming impact. This technology is particularly beneficial for commercial food and drink refrigeration, allowing clients to effectively lower indirect greenhouse gas emissions. By prioritizing sustainability, Barocal aims to contribute to a more environmentally friendly approach to refrigeration.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, founded in 2017. It operates a user-centric genetic data-sharing platform that empowers individuals to contribute their genetic and health information for research purposes. The platform facilitates a direct connection between users and researchers, enabling the analysis of consented data to advance scientific understanding and personalized medicine. Sano Genetics supports a wide range of studies, including those focused on common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to choose from various research programs, the company aims to enhance recruitment for clinical trials and provide researchers with access to dynamic health and genetic datasets, ultimately contributing to the development of new treatments and cures.

Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.

Cambridge Touch Technologies, Ltd., established in 2011 and based in Cambridge, UK, specializes in developing advanced 3D touch technology for various applications. The company's core product, UltraTouch, combines a proprietary AI engine with an innovative Piezoelectric Force Film to create a simplified, yet powerful touch and force sensor architecture. This technology offers superior functionality, lower costs, and scalability to diverse device sizes and shapes, including curved and foldable ones, catering to smartphones, tablets, automotive, and industrial sectors.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Pathfinder Medical is focused on developing an innovative electronic guidance system that allows clinicians to connect blood vessels through minimally invasive techniques. This novel catheter-based technology is specifically designed for vascular access creation, addressing critical needs in the treatment of kidney failure, particularly for patients requiring hemodialysis. The system is engineered to be performed outside of the operating room, reducing the likelihood of complications and enhancing patient care. Pathfinder Medical's platform has significant potential across various clinical applications, including bypassing peripheral blockages, and operates within a substantial market valued at £1.6 billion annually.

Psyomics specializes in the development of proteomic diagnostics aimed at improving early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers web-based assessment triage designed to facilitate diagnostic and pathway prediction for mental health conditions. By integrating digital profiling with cutting-edge biological research, Psyomics enhances diagnostic accuracy and supports primary care practitioners in effectively managing their patients' mental health needs. This innovative approach digitally replicates a psychiatric assessment at the initial point of contact, thereby enabling patients to achieve better recovery outcomes from mental health disorders.

Fuel3D is a company that specializes in advanced 3D scanning technology, offering an affordable handheld scanner designed for high-quality shape and color capture across various creative applications. The scanner utilizes a unique combination of pre-calibrated stereo cameras and photometric imaging to produce detailed 3D images quickly, making it accessible to independent game developers, designers, and artists. Originally developed for the medical imaging sector at Oxford University by a team of engineers and scientists, Fuel3D's technology has been adapted for broader markets, aiming to democratize point-and-shoot 3D imaging. The company, now led by CEO Stuart Mead, focuses on providing rapid and accurate analysis of organic subjects, serving clients in fields ranging from art and animation to gaming and retail.

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Charco Neurotech is a medical technology company focused on creating non-invasive wearable devices aimed at enhancing the quality of life for individuals with Parkinson's disease. The company's primary innovation involves a wearable device that modulates sensory dysfunction, which aids users in improving their movement speed and overall mobility. By addressing specific challenges faced by those living with Parkinson's, Charco Neurotech seeks to empower individuals to maintain a more active and normal lifestyle.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.

Cheesecake Energy specializes in the development of advanced thermal and compressed air energy systems aimed at storing energy generated from intermittent renewable sources. By transforming this energy into reliable, on-demand power, the company addresses the challenges of energy supply consistency. Their innovative technology utilizes compressed air and thermal energy storage methods, which leverage industrial components that are readily available in the market. This approach not only enhances the efficiency of energy storage but also allows clients to acquire durable storage solutions at competitive prices.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

Helio Display Materials is a developer of innovative perovskite-based materials aimed at enhancing display technology. The company focuses on creating materials that enable brighter and more colorful displays while significantly reducing power consumption. By leveraging metal halide perovskites, which can be synthesized using low-temperature processes and earth-abundant precursor materials, Helio aims to produce vibrant and efficient light-emitting technologies for televisions and displays. The company emphasizes collaboration with scientific and industry experts to expedite research and development, ensuring a strong scientific foundation for its intellectual property. Helio's mission is to improve display performance and efficiency, ultimately providing a superior visual experience.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Nyobolt is a technology developer focused on high-power battery solutions for the automotive industry. Founded in 2020 and based in Cambridge, United Kingdom, the company specializes in innovative battery technology that incorporates new materials and advanced cell designs. Nyobolt's batteries are designed to offer rapid charging capabilities and significant energy storage, catering to the demands of high-power automotive applications. By leveraging efficient software control and power electronics, Nyobolt aims to enhance the performance and reliability of electric vehicles, contributing to the advancement of sustainable transportation.

Echion Technologies, founded in 2017 and based in Cambridge, United Kingdom, specializes in developing advanced anode materials for lithium-ion (Li-ion) batteries. Their proprietary XNO® material offers faster charging times, longer lifespans, and improved safety compared to traditional options. The company targets the heavy-duty electric vehicle market, aiming to enhance efficiency and sustainability within the transportation sector by providing optimized power anode materials for cost-effective battery production.

Bonnet Ltd. is a London-based company established in 2019 that specializes in charging-as-a-service solutions for electric vehicle drivers. Its platform simplifies the charging experience by enabling users to access a wide network of public chargers through a single application, eliminating the need for separate registrations with individual charging networks. By streamlining the process, Bonnet aims to enhance convenience for both drivers and businesses, facilitating easier and more efficient electric vehicle charging.

Arkivum Limited, established in 2011 and based in Chippenham, UK, specializes in long-term data management and digital preservation solutions. Serving data-intensive and regulated industries such as healthcare, life sciences, and finance, Arkivum provides a suite of products including Arkivum/100, Arkivum/1+1, Arkivum/OnSite, Perpetua, Archive Builder Toolkit, and QStar Network Migrator. These solutions ensure data is securely stored, accessible, and usable for extended periods, with a focus on data integrity and compliance. Arkivum's services are delivered through a network of reseller and OEM channel partners.

Fresh Check is a simple sticker that you put inside the packaging of food that changes colour when your food has actually gone off, not when the use-by date says so.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Porotech is a spin-out from the University of Cambridge that specializes in the development of wide-bandgap gallium nitride (GaN) semiconductors. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on applying advanced material technologies to maximize the potential of GaN. This innovation aims to transform the electronics industry by enhancing the efficiency of light-emitting diodes and other electronic devices, thereby enabling a wide range of applications. Through its cutting-edge approaches, Porotech is positioned to contribute significantly to the advancement of energy-efficient semiconductor solutions.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Versed AI is a technology company that specializes in supply chain intelligence, utilizing advanced natural language processing and machine learning techniques. The company develops a software-as-a-service platform that automatically extracts and visualizes supply chain data from various text documents, creating comprehensive supply chain maps. This enables organizations to monitor, manage, and mitigate potential risks within their supply chains by identifying buyer-supplier relationships and potential points of failure. Founded by Simon Baker and Fenelle Boyle, Versed AI's innovative approach helps businesses enhance their understanding of supply chain dynamics and improve their operational resilience.

Machine Discovery is a spin-out from the University of Oxford focused on commercializing advanced machine learning technology. The company has developed a simulation management platform that utilizes proprietary neural network technology to enhance the efficiency of compute-intensive tasks. This platform enables clients to conduct simulations with minimal data input while achieving a high level of accuracy, specifically 99.9% fidelity. By accelerating costly calculations, Machine Discovery provides valuable statistical insights that aid clients in speeding up their innovation processes, thus addressing critical demands in various sectors.

Mogrify is a biotechnology company that has created a proprietary suite of platform technologies aimed at advancing cellular reprogramming and maintaining cell identity. Developed over 12 years through an international research collaboration, its platforms, MOGRIFY and epiMOGRIFY, leverage big data, next-generation sequencing, and gene regulatory networks to predict the necessary transcription and growth factors for generating any desired human cell type from various sources. Mogrify's technology can enhance existing stem-cell programming methods or facilitate direct transdifferentiation between mature cell types, thereby generating functional cells for therapeutic applications. The company focuses on developing innovative in vivo reprogramming therapies targeted at conditions in ophthalmology, otology, metabolic diseases, and other degenerative disorders. Positioned to tap into a regenerative medicine market projected to reach $150 billion by 2028, Mogrify pursues commercialization through therapy development, co-development partnerships, and the application of its platforms in diverse therapeutic and non-therapeutic areas.

iKVA is an AI knowledge management software company that develops a platform designed to discover and transform data into actionable business insights. Utilizing advanced machine learning, natural language processing, and semantic technology, iKVA indexes unstructured data from various sources, including document archives, emails, chat, and videos. This capability allows businesses to significantly reduce the time spent searching for information while minimizing risks by ensuring that accurate and relevant information is readily available. The company's focus on harnessing AI technology positions it as a key player in improving organizational efficiency and decision-making processes.

Zentraxa is a biotechnology company specializing in the design, production, and testing of innovative synthetic biopolymers. Utilizing its proprietary technology platform, Zentide, the company advances the capabilities of peptide synthesis by overcoming traditional bio-design limitations through a universal manufacturing process. Zentraxa's biopolymers are engineered to support diverse medical applications, including the development of biological adhesives. This unique approach allows clients to enhance their research and development efforts, positioning Zentraxa as a leader in the field of synthetic biopolymers.

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of biological substances such as proteins, DNA, and small molecules. The company focuses on simplifying the analysis of these biomolecules for pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate the analysis of biomolecular interactions, including protein interaction analysis, enabling researchers to achieve sensitive and timely medical diagnoses. Through its innovative technology, Abselion enhances the efficiency of biomedical research and contributes to advancements in medical diagnostics.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Carbometrics is a specialist chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Founded by the team behind the successful development of a glucose-binding molecule platform, the company leverages over 20 years of research from Professor Anthony Davis’ group at the University of Bristol. Carbometrics aims to create a robust and accurate glucose sensing platform that will lead to an innovative Continuous Glucose Monitoring (CGM) solution, enabling individuals with diabetes to monitor their glucose levels more effectively. Following the sale of their previous venture, Ziylo, to Novo Nordisk, the founders are committed to developing advanced technologies to improve the management of diabetes and enhance patients' quality of life.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company specializes in identifying new druggable targets for cancer and other unmet medical needs through its innovative Site-Seeker platform. This platform systematically reveals cryptic druggable sites within the human genome and connects them to therapeutic functions in a live-cell context. By utilizing functionally validated protein fragments, PhoreMost informs the design of small molecule drugs that can be developed into targeted therapies. The company collaborates with a global network of academic and industrial partners to efficiently advance novel therapies to market, aiming to reduce costs and improve accessibility for patients.

Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on improving access to blood tests through innovative healthcare monitoring devices. Established in 2014, the company offers products such as Aptus, which facilitates haemoglobin and haematocrit testing for various applications, including health screening and maternal and child health. Additionally, Entia provides Affinity, a device designed for cancer patients to monitor their blood counts at home, thereby reducing the risk of infection and minimizing the need for hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, business development, and innovation, aimed at enhancing the management of health conditions from the comfort of patients' homes.

Cytoseek Limited is a biotechnology company based in Bristol, United Kingdom, that specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Founded in 2017 as a spinout from the University of Bristol, Cytoseek focuses on cell membrane augmentation technology, which enhances the functionality of cell therapies by enabling tissue-specific targeting and improving cell survivability. The company is currently conducting proof of principle studies to validate the efficacy of its technologies and is actively seeking partnerships with other cell therapy organizations to advance its products towards clinical application, with the overarching goal of improving human health.

TextMine is an AI-powered knowledge base designed to streamline the management of business-critical documents, such as invoices, contracts, and compliance reports. By utilizing patented knowledge graph technology, TextMine consolidates data into a single operational layer, enhancing the usability and searchability of contract data at scale. This approach facilitates proactive decision-making and improves data transparency, enabling organizations to create documents more uniformly and efficiently. As a result, TextMine assists companies in saving time and reducing costs while minimizing risk and enhancing compliance.